Hydrocortisone Momaja (Hydrocortisone Sodium Succinate)

Hydrocortisone Momaja is used in clinical settings where immediate glucocorticoid activity is required. These indications reflect the need for rapid systemic exposure and potent anti‑inflammatory activity.

• Management of primary or secondary adrenal insufficiency.
• Treatment of acute adrenal crisis, including stress dosing.
• Adjunct therapy for septic shock to support hemodynamic stability.
• Rapid control of severe inflammatory or allergic reactions such as anaphylaxis.
• Peri‑operative glucocorticoid replacement in patients with known adrenal deficiency.
• Emergency use in pediatric adrenal emergencies when oral therapy is not feasible.

• Hydrocortisone sodium succinate is a water‑soluble pro‑drug that is rapidly hydrolyzed to hydrocortisone after intravenous or intramuscular administration. The active hydrocortisone binds to intracellular glucocorticoid receptors, translocates to the nucleus, and modulates gene transcription. This interaction suppresses pro‑inflammatory cytokine production, decreases leukocyte migration, and stabilizes lysosomal membranes, resulting in potent anti‑inflammatory and immunosuppressive effects. The effect is dose‑dependent and peaks within minutes after injection.

Hydrocortisone Momaja may cause a range of adverse reactions, varying from mild to severe.

Common

• Transient hyperglycemia or elevated blood glucose.
• Fluid retention leading to mild peripheral edema.
• Increased blood pressure or systolic elevation.
• Injection‑site pain, erythema, or irritation.
• Mild gastrointestinal discomfort such as nausea or dyspepsia.
• Mood changes including irritability or insomnia.
• Transient increase in white blood cell count.
• Mild headache or dizziness.

Serious

• Suppression of the hypothalamic‑pituitary‑adrenal axis causing secondary adrenal insufficiency.
• Severe or opportunistic infections due to immunosuppression.
• Anaphylactic or severe hypersensitivity reactions, including bronchospasm.
• Electrolyte disturbances such as hypokalemia or hypernatremia.
• Psychiatric disturbances such as depression, psychosis, or mania.
• Osteonecrosis of the femoral head with prolonged high‑dose therapy.

When prescribing Hydrocortisone Momaja, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Do not use in patients with known hypersensitivity to hydrocortisone sodium succinate or any excipients.
• Assess for active or latent infections; glucocorticoids can exacerbate bacterial, viral, or fungal infections.
• Use caution in individuals with uncontrolled diabetes mellitus, as hyperglycemia may worsen.
• Monitor blood pressure and fluid balance in patients with hypertension or congestive heart failure.
• Consider potential fetal risk; avoid unless benefits outweigh risks during pregnancy.
• Taper gradually after prolonged therapy to prevent adrenal insufficiency.

Hydrocortisone Momaja can alter the pharmacokinetics or pharmacodynamics of several concomitant medicines.

Avoid

• Strong CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce glucocorticoid exposure.
• Live vaccines, because immunosuppression can diminish vaccine efficacy.
• Systemic antifungal agents such as ketoconazole that can increase glucocorticoid levels.

Use with caution

• Anticoagulants (warfarin) – glucocorticoids may enhance anticoagulant effect.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – increased risk of gastrointestinal ulceration.
• Diuretics – may exacerbate electrolyte disturbances.
• Antidiabetic agents – may require dose adjustment due to hyperglycemia.
• Macrolide antibiotics (e.g., erythromycin) – may increase glucocorticoid plasma concentrations.
• Psychiatric medications (e.g., lithium) – glucocorticoids may potentiate neuropsychiatric effects.